Kicking off Miami Breast with our Regional Director Antonio Paternostro, alongside Dr. Eleni Tousimis (Miami Cancer Institute) and Dr. Pat Borgen (Maimonides Medical Center). Don’t miss Dr. Borgen’s Plenary Session on Genomic Profiling in DCIS tomorrow morning at 8:20 AM.

“What do you mean by stage zero? Do you have cancer, or do you not have cancer?” DCIS may be labeled “stage zero,” but treatment decisions can be complex. Experts discuss recurrence risk & shared decision-making. Listen: https://t.co/OwnIpuDjV5

Let’s connect at #SSO2026. Meet the PreludeDx team for dinner or 1:1 conversation about DCISionRT® and AidaBREAST™ for early-stage breast cancer. Reach out to your Regional Director to set up a time. #BreastCancer #SurgicalOncology

Heading to Miami Breast Cancer Conference, March 5 to 8? Visit PreludeDx at Booth #T4 to discuss DCISionRT® and AidaBREAST™ and join us Thursday for Posters 048 and 049 on radiation decision insights in DCIS and early-stage invasive breast cancer.

“DCIS wasn’t a journey for me — it was a nightmare.” After multiple surgeries and nonstop treatment decisions, Beth shares how DCISionRT® helped her navigate her DCIS diagnosis and learned to advocate for herself. Read her full story on our blog: https://t.co/jJkO3kZbLo

There are so many highlights from this year’s National Sales Meeting! We heard from inspiring voices reinforcing why personalized, biology-driven care matters—for physicians and patients. Grateful for the insight, energy, and momentum as we advance precision medicine together.

DCIS is often called “stage zero,” but decisions aren’t simple. On Breast Cancer Conversations, Leona Hamrick, DHSc, PA-C (VP, Global Medical Affairs, PreludeDx) discusses treatment trade-offs and how DCISionRT® supports shared decision-making. Podcast: https://t.co/UgpUxR2o5X

Looking to see if DCISionRT is in your area? Our website shows where physicians are who order our test. Enter your zip code, check out the map, then click on the link to contact our team—we will send you the information! https://t.co/HBdOuzu1dO

We’re honored to welcome MiMi Reyes as Senior Vice President of Operations at PreludeDx. MiMi brings over 25 years of expertise in diagnostics and medical devices to our team. Read more here: https://t.co/YApqIzVrIa

This video highlights why informed choice is so critical after a breast cancer diagnosis. At PreludeDx, we provide tools like DCISionRT® and AidaBreast™ that give patients and physicians clarity, confidence, and personalized insights to guide their radiation therapy decisions.

“The DCISionRT assay is adding information that is completely novel.” Dr Atif Khan, Radiation Oncologist @MSKCancerCenter. Full Presentation from #ASTRO25: https://t.co/AeFAggkoTA #DCIS #PreludeDX

Happy New Year from PreludeDx! Here’s to a healthy, hopeful, and impactful 2026. #PreludeDx #BreastCancerCare #PrecisionOncology

Happy Holidays from PreludeDx! Wishing you a season filled with peace, health, and hope. #PreludeDx #BreastCancerCare #PrecisionOncology

Personalized care and genomic testing are changing how breast cancer is treated. Michael Berry, MD, President of ASBrS, shares insights in this recent article: https://t.co/5PnzYornXn

This video highlights why informed choice is so critical after a breast cancer diagnosis. At PreludeDx, weprovide tools like DCISionRT® and AidaBreast™ that give patients and physicians clarity, confidence, and personalized insights to guide their radiation therapy decisions.

At #SABCS25, Dr. Bruce Mann and Troy Bremer, PhD presented new independent validation data for AidaBreast. The study demonstrated AidaBreast provides individualized insight into recurrence risk and predicts radiation therapy benefit. https://t.co/JPgXxirZ8i

Proud to be featured in USA TODAY as part of a national Breast Health Campaign now available in print and online. Read about our personalized tools that are making a difference in early-stage breast cancer care. https://t.co/OybS5ukOCf #BreastCancerCare #BreastHealth

This marks an important moment for personalized breast cancer care. “AidaBreast provides a new level of clarity for women with early-stage invasive breast cancer.” said Dan Forche , President and CEO of PreludeDx. Read the full release here: https://t.co/IlsO9UnHZg

X: We’re excited to be at #SABCS25, and can’t wait to connect with you! You can find us at booth #1314. See you soon! #DCISionRT #AidaBreast #PreludeDx

Honored to host Congresswoman Young Kim (Orange County, CA) at PreludeDx. Our team shared how DCISionRT® helps women with early-stage breast cancer make personalized treatment decisions. Grateful for her interest in ensuring access and coverage for these lifechanging tools! #DCIS